Proteomics International is applying its Promarker™ technology platform to create new diagnostic tests for chronic diseases with unmet medical need. Promarker™ is Proteomics International’s proprietary mass spectrometry-based technology platform for discovering, verifying, and analytically validating diagnostic protein biomarkers for diseases and other conditions. PromarkerD, the Company’s flagship predictive test for diabetic kidney disease, was produced and validated using Promarker™.
The Company’s protein biomarker discovery program is currently investigating the protein ‘fingerprints’ associated with the following diseases:
Status update: Discovery study completed; Proof of Concept study pending
Endometriosis affects one in ten women in their reproductive years (15-49) and costs $12,000 per year for every person diagnosed – both incidence and health burden are comparable with diabetes. This gynaecological condition causes chronic pain and infertility but is often difficult to diagnose. On average, it takes 8.5 years for women to be diagnosed from their first symptoms, and the current gold standard for detection is invasive surgery.
The lack of understanding about endometriosis has hidden the serious economic burden the disease places on society. The condition is estimated to cost Australia $7.7 billion annually, two thirds of which is attributed to lost productivity.
Results to date have identified several potential biomarkers for the disease, which now require verification using the next step in the pipeline.
Parasite infections: Giardia
Status update: Discovery study completed; Proof of Concept study on-going
Giardia is one of the most common parasitic human diseases globally. About 10% of those infected have no symptoms. In 2013, there were about 280 million people worldwide with symptomatic giardiasis. In some developing countries Giardia is present in 30% of the population, and in the USA it is estimated that it is present in 3-7% of the population.
The risk for human health is that some Giardia strains that affect pets can cross into humans (zoonotic), whilst others are host specific. Current tests cannot easily differentiate between the host specific and zoonotic strains.
Proteomics International is collaborating with Murdoch University Veterinary School and a leading US veterinary company to develop an improved diagnostic test that is strain specific, and could be used to test if infected pets present a risk to their owners.
Asthma and Chronic Obstructive Pulmonary Disease (COPD)
Status update: Ethics approved; Discovery study pending
In December 2017, Proteomics International joined forces with the Busselton Population Medical Research Institute to improve the diagnosis and treatment of lung conditions such as asthma and chronic obstructive pulmonary disease, which cost health care systems tens of billions of dollars a year.